Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer

Clinicopathological and Therapeutic Significance of CXCL12 Expression in Lung Cancer

(2017) H. Imai et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Molecular Biology of Lung Cancer: Clinical Implications

(2011) Jill E. Larsen et al.   CLINICS IN CHEST MEDICINE

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer

(2011) Noriaki Sunaga et al.   INTERNATIONAL JOURNAL OF CANCER

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

(2011) Antonio Marchetti et al.   JOURNAL OF CLINICAL ONCOLOGY

Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

(2011) N. Sunaga et al.   MOLECULAR CANCER THERAPEUTICS

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

(2010) Kenichi Suda et al.   CANCER AND METASTASIS REVIEWS

Biologic Correlation of 2-[18F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors

(2010) Kyoichi Kaira et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells

(2009) Meng Zhao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

(2009) M. Sun et al.   CLINICAL CANCER RESEARCH

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations

(2009) S. Morita et al.   CLINICAL CANCER RESEARCH

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines

(2009) Jeet Gandhi et al.   PLoS One

Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells

(2009) Junichi Soh et al.   PLoS One

Epiregulin expression by Ets-1 and ERK signaling pathway in Ki-ras-transformed cells

(2008) Min-Chul Cho et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Intratumoral Epiregulin Is a Marker of Advanced Disease in Non-Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells

(2008) J. Zhang et al.   Cancer Prevention Research

Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops

(2008) A. F. Gazdar et al.   Cancer Prevention Research

Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer

(2008) C. A. Pratilas et al.   CANCER RESEARCH

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

(2008) H. Yamamoto et al.   CANCER RESEARCH

Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes

(2008) Xingya Wang et al.   MOLECULAR CARCINOGENESIS

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt

(2008) Kai Hu et al.   ORAL ONCOLOGY